-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
In 1854, london was rocked by a cholera epidemic that killed approximately 10,000 people. Using what are now considered classical epidemiological methods, Dr. John Snow traced the source of at least 500 of the infections to a single water pump at Broad Street, validating his theory that cholera was a water-borne disease 29 years before the etiologic agent was discovered by Robert Koch; removing the pump handle stopped the outbreak in that area.
-
I was asked earlier this week to see a patient with candidemia. The patient had severe cirrhosis and had previously had placement of a transjugular intrahepatic portosystemic shunt (TIPS) for control of complications of portal hypertension.
-
In this study, 2,499 hiv-seronegative men or transgender females who have sex with men (MSM) were randomized to daily TDF/FTC vs. placebo in a multicenter, controlled trial with clinical sites in North America, Latin America, Thailand, and Africa.
-
Group B streptococcal (GBS) disease is the leading cause of early-onset neonatal sepsis (within the first week of life) in the United States.
-
-
-
Acetaminophen (known as paracetamol outside the United States) is the most commonly used analgesic in the world, usually considered to be safe and benign.
-
Clinicians who send samples to the 95% of U.S. laboratories that test for Clostridium difficile infection using an enzyme-immunoassay (EIA) for toxins A and B are often frustrated by a negative laboratory result that doesn't fit their clinical impression or their olfactory suspicions.
-
Central line-associated infections, particularly bloodstream infections (BSI), remain a huge issue in our technological age.
